At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 4, 2026 at 09:17 ET
Alpha Tau announced 100% local disease control in evaluable patients from pooled first-in-human trials of Alpha DaRT for pancreatic cancer, presented at DDW 2026. The favorable safety and efficacy data in heavily pre-treated patients represent a significant milestone for the company's lead product candidate.
- 100% local disease control in 19 evaluable patients (79% stable disease, 21% partial response)
- Only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks
- First presentation of Alpha DaRT at a major gastroenterology conference (DDW 2026)
- Treatment delivered via EUS, designed for integration into standard GI workflow
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access